NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Oncotelic Therapeutics' Biomarker Study Publication and Company Overview
TL;DR
Oncotelic Therapeutics' research reveals context-dependent biomarkers, offering potential competitive advantages in developing targeted cancer therapies for HCC and PDAC.
The study analyzes DNMT3A and GMPS biomarkers across 7,000+ patient datasets, demonstrating how immune composition and metabolic pathways shape prognostic significance in liver and pancreatic cancers.
This research advances translational oncology through structured mentorship, potentially improving treatment outcomes for cancer patients and making tomorrow better through enhanced personalized medicine approaches.
A peer-reviewed article shows how biomarker relevance in cancers depends on immune context, highlighting the fascinating complexity of tumor microenvironment interactions.
Found this article helpful?
Share it with your network and spread the knowledge!
Oncotelic Therapeutics, in collaboration with the Brush and Key Foundation, announced the publication of a peer-reviewed research article titled 'Comparative Tumor Microenvironment Analysis for HCC and PDAC Using KMplotter' in the International Journal of Molecular Sciences.
The study analyzes the prognostic significance of biomarkers DNMT3A and GMPS across hepatocellular carcinoma (HCC) and pancreatic ductal adenocarcinoma (PDAC) using survival, transcriptomic, and tumor microenvironment data from more than 7,000 patients.
The study demonstrates that biomarker relevance is highly context-dependent, shaped by immune composition, metabolic reprogramming, and innate immune signaling pathways.
Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers.
Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (DIPG) through OT-101, melanoma through CA4P, and Acute Myeloid Leukemia (AML) through OXi 4503.
Oncotelic is developing AL-101 for Parkinson's Disease, Erectile Dysfunction (specifically for treatment failure patients who don't respond to PDE5 inhibitors), and Female Sexual Dysfunction.
Over 60,000 new patients are diagnosed with PD annually in the US, with over 1 million current patients expected to increase to over 1.2 million by 2030, and approximately 10 million sufferers globally.
Oncotelic acquired PointR Data Inc. in November 2019 and acquired AL-101 during the 4th quarter of 2021.
To view the full press release about the study, visit https://nnw.fm/ucbzV.
The study highlights the role of structured mentorship in advancing translational oncology research, though specific details about this mentorship are not provided in the content.
Curated from InvestorBrandNetwork (IBN)
